Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References Leqvio® US launch - steadily building the foundation Expect continued steady ramp through H1 2023 Driving broad HCP adoption HCPs initiating a patient¹ on LeqvioⓇ -800 ~2400 ~4800 ■ Q3 sales USD 34m YCE AZ N 1 GROWTH K &K LEQVIO® ■ HCP adoption doubled vs. Q2, focus on breadth + depth ■ Broad access: 70% coverage at-or-near label ■ Favorable affordability: 2/3 of patients with zero co-pay ■ Free Trial Offer launched to support patient initiation² Working through practice logistics and administration ■ AHA: 4-year efficacy and safety data to be presented (ORION-3) Q1 2022 Q2 2022 Q3 2022 HCP Healthcare Professional AHA - American Heart Association 1. Either prescribe LeqvioⓇ to a patient based on service center data, data on file or have ordered through Free Trial Offer program. 2. Free Trial Offer program allows HCP to order one free dose per lifetime per patient. *Leqvio® is administered initially, again at 3 months, and then once every 6 months. 12 Investor Relations | Q3 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation